Sign in

You're signed outSign in or to get full access.

Yun Zheng

Vice President and Equity Research Analyst at Woodbush

Yun Zheng is a Vice President and Equity Research Analyst at Woodbush Wealth Partners, specializing in consumer and retail sector research with a focus on specialty retail, apparel, and luxury goods. She covers key companies including Lululemon Athletica (LULU), VF Corporation (VFC), Tapestry (TPR), and Levi Strauss & Co. (LEVI), achieving a strong performance track record with a 68% success rate and average return of 14.2% per rating on TipRanks, ranking in the top 10% of retail analysts. Zheng joined Woodbush in 2022 after prior roles at BMO Capital Markets (2018-2022) and Janney Montgomery Scott (2015-2018), starting her career as a junior analyst following her MBA; she holds Series 7, 63, and 86/87 FINRA licenses and is a CFA charterholder.

Yun Zheng's questions to Ascendis Pharma (ASND) leadership

Question · Q4 2025

Yun Zheng asked if it is reasonable to expect the once-weekly TransCon PTH program to enter the clinic in 2026 or if there is no need to rush. He also inquired about the most efficient clinical pathway to approval, given the goal of matching the PK profile to the daily YORVIPATH product.

Answer

Jan Møller Mikkelsen, President and Chief Executive Officer, explained that if the PK profile in healthy volunteers or hypopara patients demonstrates bioequivalence to Europat's daily dose over the entire week, it would significantly simplify and expedite the clinical trial process, ensuring expected safety and tolerability. This bioequivalence is the program's aspiration.

Ask follow-up questions

Fintool

Fintool can predict Ascendis Pharma logo ASND's earnings beat/miss a week before the call